Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Meta-static Breast Cancer Patients Treated within the TANIA Phase III Trial.

Rinnerthaler, G; Gampenrieder, SP; Hackl, H; Steiner, M; Monzo-Fuentes, C; Melchardt, T; Magnes, T; Huemer, F; Westphal, T; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R. J Clin Med. 2020 Jun 1;9(6):1663. doi: 10.3390/jcm9061663.

Comparison of high tone therapy and transcutaneous electrical nerve stimulation therapy in chemotherapy-induced polyneuropathy.

Schaffler-Schaden, D; Sassmann, R; Johansson, T; Gampenrieder, SP; Rinnerthaler, G; Lampl, K; Herfert, J; Lenzhofer, C; Landkammer, YT; Rieder, F; Greil, R; Flamm, M; Niebauer, J. Medicine (Baltimore). 2020; 99(19): e20149.

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study.

Schlenk, RF; Paschka, P; Krzykalla, J; Weber, D; Kapp-Schwoerer, S; Gaidzik, VI; Leis, C; Fiedler, W; Kindler, T; Schroeder, T; Mayer, K; Lübbert, M; Wattad, M; Götze, K; Horst, HA; Koller, E; Wulf, G; Schleicher, J; Bentz, M; Greil, R; Hertenstein, B; Krauter, J; Martens, U; Nachbaur, D; Abu Samra, M; Girschikofsky, M; Basara, N; Benner, A; Thol, F; Heuser, M; Ganser, A; Döhner, K; Döhner, H. J Clin Oncol. 2020; 38(6):623-632.

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoad-juvant phase II study (ABCSG 34).

Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stoger, H; Pichler, A; Petru, E; Bjelic-Radisic, V; Greil, R; Rudas, M; Tea, MKM; Wette, V; Petzer, AL; Sevelda, P; Egle, D; Dubsky, PC; Filipits, M; Fitzal, F; Exner, R; Jakesz, R; Balic, M; Tinchon, C; Bago-Horvath, Z; Frantal, S; Gnant, M. EUR J CANCER. 2020; 132: 43-52.

Dabrafenib plus trametinib in patients with BRAF.

Subbiah, V; Lassen, U; EElez, E; Italiano, A; Curigliano, G; Javle, M; de Braud, F; Pra-ger, GW; Greil, R; Stein, A; Fasolo, A; Schellens, JHM; Wen, PY; Viele, K; Boran, AD; Gasal, E; Burgess, P; Ilankumaran, P; Wainberg, ZA. Lancet Oncol. 2020; 21(9):1234-1243.

TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia.

Szenes, E; Harzschel, A; Decker, S; Tissino, E; Pischeli, J; Gutjahr, JC; Kissel, S; Pen-nisi, S; Hopner, JP; Egle, A; Zaborsky, N; Dierks, C; Follo, M; Chigaev, A; Zucchetto, A; Greil, R; Gattei, V; Hartmann, TN. LEUKEMIA. 2020; 34(9): 2498-2502.

A cross-trial comparison of single-agent ibrutinib.

Tedeschi, A; Greil, R; Demirkan, F; Robak, T; Moreno, C; Barr, PM; Anz, B; Simpson, D; Gaidano, G; Bairey, O; Stevens, D; Gill, D; Flinn, IW; Kipps, TJ; Burger, JA; Lin, J; Webb, T; Fedorov, V; Styles, L; Gribben, JG. Haematologica. 2020; 105(4):e164-e168.

Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.

Wagner, SM; Melchardt, T; Egle, A; Magnes, T; Skrabs, C; Staber, P; Simonitsch-Klupp, I; Panny, M; Lehner, B; Greil, R; Keil, F; Jäger, U; Sillaber, C. Eur J Haematol. 2020; 104(3):251-258.

Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.

Wagner, SM; Melchardt, T; Greil, R. DRUG TODAY. 2020; 56(3): 195-202.

Alemtuzumab plus CHOP versus CHOP in elderly patients with peri-pheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.

Wulf, GG; Altmann, B; Ziepert, M; DxxxAmore, F; Held, G; Greil, R; Tournilhac, O; Relander, T; Viardot, A; Wilhelm, M; Wilhelm, C; Pezzutto, A; Zijlstra, JM; Van Den Neste, E; Lugtenburg, PJ; Doorduijn, JK; van Gelder, M; van Imhoff, GW; Zettl, F; Braulke, F; Nickelsen, M; Glass, B; Rosenwald, A; Gaulard, P; Loeffler, M; Pfreund-schuh, M; Schmitz, N; Trumper, L. Leukemia . 2020 May 7. doi: 10.1038/s41375-020-0838-5. Online ahead of print.